Et-29
Based on 2 publication(s) in Google Scholar
Et-29 (NRD167) is a selective SIRT5 inhibitor. Et-29 increases the levels of total protein succinylation and citrate synthase succinylation in cells. Et-29 reduces serum CTX-I levels and blocks Ferroptosis by downregulating the SIRT5/ACSL4/LPCAT3/ALOX15 axis and restoring antioxidant defense. Et-29 decreases bone resorption and improves trabecular bone mass and microarchitecture. Et-29 is applicable for research related to osteoporosis and hepatocellular carcinoma.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 2166487-23-4
- Formula: C34H46N6O6S
- Molecular Weight:666.83
-
Storage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Et-29
More
Biological Activity
Description
|
ACSL4 |
SIRT5 |
In Vitro
ET-29 (40 μM; 24 h) reverses Arachidonic acid (HY-109590)-induced dysregulation of the SIRT5-ACSL4/LPCAT3/ALOX15 ferroptosis pathway in SK-HEP-1 and Hepa1-6 cells, restoring GPX4 and xCT expression toward control levels[3].
ET-29 (40 μM; 24 h) attenuates multiple ferroptosis-associated phenotypes induced by arachidonic acid in SK-HEP-1 and Hepa1-6 cells, including iron accumulation, ROS elevation, lipid peroxidation, and mitochondrial depolarization, while exhibiting no significant effect on these parameters under basal conditions[3].
Inhibition of SIRT5 by Et-29 increases both global protein succinylation and citrate synthase succinylation in HepG2 hepatocellular carcinoma cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SK-HEP-1 human hepatocellular carcinoma cells, Hepa1-6 murine hepatoma cells
-
Concentration:40 μM (alone); 40 μM (co-treatment with 30 μM AA, added 1 hour prior)
-
Incubation Time:24 h
-
Result:Showed no significant alteration of the protein expression levels of SIRT5, ACSL4, LPCAT3, ALOX15, GPX4, or xCT compared with control cells when administered alone.
Markedly reversed the AA-induced upregulation of SIRT5, ACSL4, LPCAT3, and ALOX15, as well as the AA-induced downregulation of GPX4 and xCT, as confirmed by semiquantitative band intensity analysis.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:OVX-induced osteoporosis[1]
-
Dosage:Not specified
-
Administration:i.p.; every other day; 5 weeks
-
Result:Significantly decreased the serum level of CTX-I.
Improved trabecular bone microstructure.
Significantly increased trabecular bone vBMD, BV/TV, BS/TV, and Tb.N values, but no significant improvement was observed in cortical bone microstructural parameters.
Chemical Information
-
CAS No. 2166487-23-4
-
Appearance Solid
-
Molecular Weight 666.83
-
Formula C34H46N6O6S
-
Color White to off-white
-
SMILES
O=C(OCC1=CC=CC=C1)N[C@@H](CCCCNC(NCCC(OCC)=O)=S)C(N[C@H](C(NC(C)C)=O)CC2=CNC3=CC=CC=C23)=O
-
Synonyms
NRD167
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Acetylation of GPRC5A at Lys348 facilitates cisplatin resistance and promotes the recurrence and poor prognosis in ovarian cancer. [Abstract]2026 May:362:152113. PMID: 42009151 -
bioRxiv
2023 May 9:2023.05.08.539908. PMID: 37215033
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (149.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (3.75 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[2]. Rajabi N, et al. Mechanism-Based Inhibitors of the Human Sirtuin 5 Deacylase: Structure-Activity Relationship, Biostructural, and Kinetic Insight. Angewandte Chemie (International ed. in English). 2017 Nov 20;56(47):14836-14841. [Content Brief]
[3]. Xue P, et al. Arachidonic acid induces ferroptosis in hepatocellular carcinoma via the SIRT5-ACSL4/LPCAT3/ALOX15 axis, leading to lipid peroxidation and mitochondrial dysfunction. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2025 Nov 25;148:157450. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4996 mL | 7.4982 mL | 14.9963 mL | 37.4908 mL |
| 5 mM | 0.2999 mL | 1.4996 mL | 2.9993 mL | 7.4982 mL | |
| 10 mM | 0.1500 mL | 0.7498 mL | 1.4996 mL | 3.7491 mL | |
| 15 mM | 0.1000 mL | 0.4999 mL | 0.9998 mL | 2.4994 mL | |
| 20 mM | 0.0750 mL | 0.3749 mL | 0.7498 mL | 1.8745 mL | |
| 25 mM | 0.0600 mL | 0.2999 mL | 0.5999 mL | 1.4996 mL | |
| 30 mM | 0.0500 mL | 0.2499 mL | 0.4999 mL | 1.2497 mL | |
| 40 mM | 0.0375 mL | 0.1875 mL | 0.3749 mL | 0.9373 mL | |
| 50 mM | 0.0300 mL | 0.1500 mL | 0.2999 mL | 0.7498 mL | |
| 60 mM | 0.0250 mL | 0.1250 mL | 0.2499 mL | 0.6248 mL | |
| 80 mM | 0.0187 mL | 0.0937 mL | 0.1875 mL | 0.4686 mL | |
| 100 mM | 0.0150 mL | 0.0750 mL | 0.1500 mL | 0.3749 mL |
Et-29 Related Classifications
HY-145651 Related Classifications
Powered by Bioz